Biotricity, Inc.

The stock remains in a deep long-term downtrend, trading far below its 200-day average and well under the prior 52-week high. The setup is still a damaged small-cap regime, with price action clustered near the lower end of the yearly range rather than rebuilding a sustained base.

Street sentiment is cautious but not broken: consensus sits at Hold with a $4 target, far above the current share price. The latest rating note kept the firm on Buy while highlighting 44% annual growth potential, but the target has not been revised since that call.

The earnings profile has been consistently better than expected, with 6 of the last 6 reported quarters beating estimates. The next watch item is whether revenue growth can keep translating into narrower losses, after FY2025 revenue rose 10.2% year over year while EPS remained negative.

No notable discretionary insider buying or selling. Recent filings are dominated by award grants to the CEO, CFO, and a director, which read as compensation-related flows rather than conviction trades.

Gross margin is strong at 81.1%, but profitability remains uneven with a -25.99% net margin and -41.01% ROE. Revenue grew 10.2% year over year, yet operating cash flow was -$2.38 million and cash of $365,145 sits far below total debt of $26.09 million.

Biotricity competes as a niche remote cardiac monitoring name, where its software-plus-device model can support high gross margins. The tradeoff is scale: the balance sheet is stretched, so the valuation still reflects a distressed microcap profile versus healthier med-tech peers.